Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet

被引:134
作者
Chan, Dick C. [1 ]
Watts, Gerald F. [1 ]
Gan, Seng Khee [1 ]
Ooi, Esther M. M. [1 ]
Barrett, P. Hugh R. [1 ]
机构
[1] Univ Western Australia, Metab Res Ctr, Sch Med & Pharmacol, Perth, WA 6009, Australia
基金
英国医学研究理事会;
关键词
C-REACTIVE PROTEIN; VISCERAL ADIPOSE-TISSUE; METABOLIC SYNDROME; CHOLESTEROL; LIVER; SIMVASTATIN; LIPOPROTEINS; REDUCTION; APO-B-100; THERAPY;
D O I
10.2337/dc09-1765
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Nonalcoholic fatty liver disease is highly prevalent in obese and type 2 diabetic individuals and is strongly associated with dyslipidemia and inflammation. Weight loss and/or pharmacotherapy are commonly used to correct these abnormalities. RESEARCH DESIGN AND METHODS - We performed a 16-week intervention trial of a hypocaloric, low-fat diet plus 10 mg/day ezetimibe (n = 15) versus a hypocaloric, low-fat diet alone (n = 10) on intrahepatic triglyceride (IHTG) content, plasma high sensitivity-C-reactive protein (hs-CRP), adipocytokines, and fetuin-A concentrations and apolipoprotein (apo)B-100 kinetics in obese subjects. ApoB-100 metabolism was assessed using stable isotope tracer kinetics and compartmental modeling; liver and abdominal fat contents were determined by magnetic resonance techniques. RESULTS - Both weight loss and ezetimibe plus weight loss significantly (all P < 0.05) reduced body weight, visceral and subcutaneous adipose tissues, insulin resistance and plasma triglycerides, VLDL-apoB-100, apoC-III, fetuin-A, and retinol-binding protein-4 and increased plasma adiponectin concentrations. Compared with weight loss alone, ezetimibe plus weight loss significantly (all P < 0.05) decreased IHTG content (-18%), plasma hs-CRP (-53%), interleukin-6 (-24%), LDL cholesterol (-18%), campesterol (-59%), and apoB-100 (-14%) levels, with a significant increase in plasma lathosterol concentrations (+43%). The LDL-apoB-100 concentration also significantly fell with ezetimibe plus weight loss (-12%), chiefly owing to an increase in the corresponding fractional catabolic rate (+29%). The VLDL apoB-100 secretion rate fell with both interventions, with no significant independent effect of ezetimibe. CONCLUSIONS - Addition of ezetimibe to a moderate weight loss diet in obese subjects can significantly improve hepatic steatosis, inflammation, and LDL apoB-100 metabolism.
引用
收藏
页码:1134 / 1139
页数:6
相关论文
共 25 条
  • [1] Beghin L, 2000, J LIPID RES, V41, P1172
  • [2] Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome
    Deushi, Michiyo
    Nomura, Mitsunori
    Kawakami, Akio
    Haraguchi, Mihoko
    Ito, Mizuho
    Okazaki, Mitsuyo
    Ishii, Hideto
    Yoshida, Masayuki
    [J]. FEBS LETTERS, 2007, 581 (29): : 5664 - 5670
  • [3] Ginsberg HN, 2000, J CARDIOVASC RISK, V7, P325
  • [4] SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
    Horton, JD
    Goldstein, JL
    Brown, MS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (09) : 1125 - 1131
  • [5] Association between human fetuin-A and the metabolic syndrome - Data from the Heart and Soul Study
    Ix, JH
    Shlipak, MG
    Brandenburg, VM
    Ali, S
    Ketteler, M
    Whooley, MA
    [J]. CIRCULATION, 2006, 113 (14) : 1760 - 1767
  • [6] Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor
    Jeu, L
    Cheng, JW
    [J]. CLINICAL THERAPEUTICS, 2003, 25 (09) : 2352 - 2387
  • [7] Fatty liver -: A novel component of the metabolic syndrome
    Kotronen, Anna
    Yki-Jarvinen, Hannele
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (01) : 27 - 38
  • [8] INVIVO STIMULATION OF LOW-DENSITY LIPOPROTEIN DEGRADATION BY INSULIN
    MAZZONE, T
    FOSTER, D
    CHAIT, A
    [J]. DIABETES, 1984, 33 (04) : 333 - 338
  • [9] Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy
    Pearson, Thomas A.
    Ballantyne, Christie M.
    Veltri, Enrico
    Shah, Arvind
    Bird, Steven
    Lin, Jianxin
    Rosenberg, Elizabeth
    Tershakovec, Andrew M.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (03) : 369 - 374
  • [10] Adipocytokines and the Metabolic Complications of Obesity
    Rasouli, Neda
    Kern, Philip A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (11) : S64 - S73